Objectives: To investigate and compare etanercept monotherapy versus combination with sDMARDs in RA patients regarding survival on drug, efficacy, quality of life and reason for discontinuation.
AB0388 RESULTS AT 3 YEARS OF AN OPTIMIZATION GUIDELINE OF BIOLOGICAL THERAPIES IN RHEUMATOID ARTHRITIS. CREATE RECORD RESULTS
• The strategy of dose reduction of biological therapies in patients with established RA that achieve sustained remission is possible in 37.3% of cases in real clinical practice (CREATE Registry) and it was maintained for 3 years.
• The probability of occurrence of relapse decreases after 2 years of treatment with an optimized regimen in those patients who have not relapsed before.
• This strategy is possible in patients with persistently controlled disease and in view of our results, it is independent of the drug administered (antiTNF versus non-antiTNF).
• After 3 years of follow-up, all patients maintained clinical remission (DAS 28 <2.6) despite relapses, and after resumption of the usual dose, all of them reached the therapeutic goal again.
• Patients who maintain clinical remission for 3 years achieve DAS28 values statistically lower than those who did not after 2 years. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.2156 
